UCB - Nettoeinkommen

Aktienkurs
239.00
Täglich Wechseln
-7.30 -2.96%
Monatlich
-5.87%
Jährlich
59.65%
Q2 Prognose
233.96




Nettoeinkommen Veränderung Datum
Alcon AG USD 217M 20M 2025-12
Almirall EUR 19.58M 7M 2025-12
Amarin USD -1.22M 6.51M 2025-12
argenx SE USD 532.95M 188.69M 2025-12
AstraZeneca USD 2.33B 207M 2025-12
Bayer EUR -3.76B 2.79B 2025-12
Galapagos EUR 782.15M 984.26M 2025-12
Genmab DKK 31M 370M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
GRIFOLS EUR 98.25M 28.72M 2025-12
Hikma Pharmaceutical USD 164M 45M 2025-12
Lonza CHF 426M 119M 2025-06
Merck EUR 319M 583M 2025-12
Novartis USD 2.41B 1.52B 2025-12
Orion EUR 90.4M 170.1M 2026-03
Recordati EUR 117.31M 7.15M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR 1.61B 2.42B 2026-03
UCB EUR 1.08B 608M 2025-12
Unibail Rodamco EUR 532.1M 123.6M 2025-12